Compare · ALZN vs CGTX
ALZN vs CGTX
Side-by-side comparison of Alzamend Neuro Inc. (ALZN) and Cognition Therapeutics Inc. (CGTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ALZN focuses on Biotechnology: Pharmaceutical Preparations, while CGTX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- CGTX is the larger of the two at $60.8M, about 10.7x ALZN ($5.7M).
- CGTX has been more active in the news (5 items in the past 4 weeks vs 1 for ALZN).
- CGTX has more recent analyst coverage (4 ratings vs 1 for ALZN).
- Company
- Alzamend Neuro Inc.
- Cognition Therapeutics Inc.
- Price
- -
- -
- Market cap
- $5.7M
- $60.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 1
- 5
- Recent ratings
- 1
- 4
Alzamend Neuro Inc.
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Cognition Therapeutics Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Latest ALZN
- Amendment: Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form RW filed by Alzamend Neuro Inc.
- Alzamend Neuro Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
- SEC Form 10-Q filed by Alzamend Neuro Inc.
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Director Ault Milton C Iii sold $3,116 worth of shares (2,000 units at $1.56), closing all direct ownership in the company (SEC Form 4)
- SEC Form PRE 14A filed by Alzamend Neuro Inc.
- SEC Form S-1 filed by Alzamend Neuro Inc.
Latest CGTX
- Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
- SEC Form 10-Q filed by Cognition Therapeutics Inc.
- Cognition Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
- Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
- SEC Form 8-K filed by Cognition Therapeutics Inc.
- Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
- Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
- Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
- Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference